KEYNOTE-671: Perioperative KEYTRUDA data presentation
KEYTRUDA® (pembrolizumab), in combination with platinum-containing chemotherapy as neoadjuvant therapy and then continued as adjuvant monotherapy for patients with resectable Stage II, IIIA or IIIB (N2) non-small cell lung carcinoma (NSCLC) (KEYTRUDA perioperative treatment)

Prescribing Information [External link]

Download our KEYNOTE-671 slide deck that discusses KEYTRUDA perioperative treatment for patients with resectable Stage II, IIIA or IIIB (N2) NSCLC.

Please refer to the KEYTRUDA Summary of Product Characteristics and Risk Minimisation Materials before prescribing KEYTRUDA. Risk Minimisation Materials are available online, from your MSD representative or from MSD Medical Information (Email: medicalinformationuk@msd.com, Phone: 0208 154 8000).

Find out more information about KEYTRUDA in NSCLC:

Supporting documentation

Prescribing Information [External link]
By clicking the link above you will leave the MSD Connect website and be taken to the emc PI portal website.